Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for PIRFENIDONE
- The Safety, Tolerability, and Pharmacokinetic Study of SC1011 in Healthy Subjects.
- Pirfenidone as a Radiosensitizer in the Treatment of Head and Neck Squamous Cell Carcinoma
- Safety, Tolerability and Pharmacokinetic Study of SC1011 in Healthy Subjects
- Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis
- A Study in Healthy Men to Test Whether BI 1015550 Influences the Amount of Nintedanib and Pirfenidone in the Blood
- A Study to Investigate Leramistat in Patients With IPF
- A Study of PMG1015 Injection in Idiopathic Pulmonary Fibrosis Subjects
- Pifenidone Prophylactic Therapy for Radiation Lung Injury in Patients Who Have Previously Received Immune Checkpoint Inhibitors
- Pirfenidone in Adult Hospitalized Patients With COVID-19
- PirfenidoneVsPlacebo as Prophylaxis Against Acute Radiation-induced Lung Injury Following HFRT in Breast Cancer Patients
- Imaging Evaluation of PLN-74809 in Participants With IPF (PLN-74809)
- Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of RXC007 in Idiopathic Pulmonary Fibrosis
- Prolonged Release Pirfenidone for Advanced Residual Liver Fibrosis (MINERVA).
- Pirfenidone Treat Myocardial Fibrosis After Acute Myocardial Infarction
- Efficacy and Immune Function of Pirfenidone in CTD-ILD
- To Evaluate the Efficacy, Safety, and Tolerability of BBT-877 in Patients With IPF
- Randomized, Crossover, Multi-Dose Pharmacokinetics of EXCL-100 Pirfenidone-Sustained Release Tablet and Esbriet in Healthy Volunteers
- Study to Assess the Safety and Tolerability of ANG-3070 in Subjects With Idiopathic Pulmonary Fibrosis
- To Evaluate Drug-drug Interactions Between HEC585 and Pirfenidone or Nintedanib in Healthy Volunteers
- RESPIRARE Phase 2 Study of Efficacy and Safety of Cudetaxestat in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- Safety and Tolerability of Pirfenidone in Acute Pancreatitis
- LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Progressive Fibrosing Interstitial Lung Disease (PF-ILD)
- A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
- Efficacy and Safety of Pirfenidone Capsules in the Treatment of Pneumoconiosis
- Pirfenidone Combined With Methylprednisolone Versus Methylprednisolone in the Treatment of CIP
- Pirfenidone Use in Asbestosis Patients: Efficacy and Prognosis
- Efficiency of Pirfenidone for the Reduction of Pulmonary Metabolic, Inflammatory and Fibrogenic Activity in Patients With Silicosis Due to Artificial Stone and Progressive Massive Fibrosis
- Pirfenidone to Prevent Fibrosis in Ards.
- Phase ll Study of HEC585 in Patients With IPF
- A Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects With Idiopathic Pulmonary Fibrosis
- Drug-drug Interaction Study With GLPG4716 and Nintedanib and Pirfenidone in Healthy Subjects
- Dedicated Drug-Drug Interaction (DDI) Study in Healthy Volunteers
- Immunosuppressant Combined With Pirfenidone in CTD-ILD
- To Evaluate Drug-drug Interactions Between DWN12088 and Pirfenidone or Nintedanib in Healthy Volunteers
- Pirfenidone vs. Nintedanib for Fibrotic Lung Disease After Coronavirus Disease-19 Pneumonia
- Evaluation of the Efficacy of Pirfenidone in Progressive Chronic Hypersensitivity Pneumonitis
- Treatment With Pirfenidone for COVID-19 Related Severe ARDS
- Evaluation of Oral ORIN1001 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
- Pirfenidone Compared to Placebo in Post-COVID19 Pulmonary Fibrosis COVID-19
- Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC
- Examination of Pirfenidone (Esbriet®) Therapy in Coal Workers' Pneumoconiosis With Pulmonary Fibrosis
- Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
- Prospective Treatment Efficacy in IPF Using Genotype for Nac Selection (PRECISIONS) Trial
- A Study to Evaluate the Efficacy and Safety of Pirfenidone With Novel Coronavirus Infection
- Trial of Pirfenidone to Prevent Progression in Chronic Kidney Disease
- Efficacy and Safety of Pirfenidone Treatment in HPS-ILD
- Jin-shui Huan-xian Granule in the Treatment of IPF
- Pirfenidone Capsule in Patients With Chronic Kidney Disease G2 and G3a Study on Safety and Pharmacokinetics
- Pirfenidone and Advanced Liver Fibrosis.
- A Study of the Pharmacokinetic Interaction Between Pirfenidone and BMS-986278 in Healthy Participants
- Evaluation of Efficacy and Safety of Pamrevlumab in Patients With Idiopathic Pulmonary Fibrosis
- Management of Progressive Disease in Idiopathic Pulmonary Fibrosis
- A Study About Safety and Efficacy of Pirfenidone to Treat Grade 2 or Grade3 Radiation-induced Lung Injury.
- Efficacy and Safety of Pirfenidone in Patient With Dermatomyositis Interstitial Lung Disease (Dm-ILD)
- Efficacy and Safety of Pirfenidone in Patient With Systemic Sclerosis-associated Interstitial Lung Disease
- A Clinical Study to Test How Effective and Safe GLPG1205 is for Participants With Idiopathic Pulmonary Fibrosis (IPF)
- A Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of SM04646 Inhalation Solution in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
- Pirfenidone and Its Role in Burn Wound Healing
- Studying the Treatment Effect of Pirfenidone in Chronic Lung Allograft Dysfunction (STOP-CLAD)
- Pilot Study of Pirfenidone in Pulmonary Fibrosis With Anti-myeloperoxydase Antibodies
- Pirfenidone for Restrictive Chronic Lung Allograft Dysfunction
- The Safety and Tolerability of Pirfenidone for BOS After HCT
- Pirfenidone for Progressive Fibrotic Sarcoidosis
- Scleroderma Lung Study III - Combining Pirfenidone With Mycophenolate
- Open-label Study to Assess the Effectiveness of Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis (IPF).
- Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC
- Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)
- A Study of Pirfenidone in Patients With Unclassifiable Progressive Fibrosing Interstitial Lung Disease
- Single Doses of GSK3008348 in Idiopathic Pulmonary Fibrosis (IPF) Participants Using Positron Emission Tomography (PET) Imaging
- Study of Efficacy and Safety of Pirfenidone in Patients With Fibrotic Hypersensitivity Pneumonitis
- Efficacy, Safety, and Tolerability Study of Pirfenidone in Combination With Sildenafil in Participants With Advanced Idiopathic Pulmonary Fibrosis (IPF) and Intermediate or High Probability of Group 3 Pulmonary Hypertension
- The Efficacy and Safety of Pirfenidone in Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction
- A Pilot Trial of Herpesvirus Treatment in Idiopathic Pulmonary Fibrosis (IPF)
- Efficacy of Intralesional Triamcinolone and 8% Topical Pirfenidone for Treatment of Keloid Scars
- Pirfenidone in Progressive Interstitial Lung Disease Associated With Clinically Amyopathic Dermatomyositis
- Phase ll Study of Pirfenidone in Patients With RAILD (TRAIL1)
- A Study to Assess the Safety and Tolerability of N-Acetylcysteine When Administered With Pirfenidone to Participants With Idiopathic Pulmonary Fibrosis (IPF)
- Evaluation of Long-Term Safety of Pirfenidone (Esbriet) in Participants With Idiopathic Pulmonary Fibrosis (IPF)
- Effect of Pirfenidone on Glomerular Filtration Rate and Albuminuria in Patients With Diabetic Nephropathy
- A Phase 2 Study of the Activity and Safety of KD025 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
- A Study of Oral Vismodegib in Combination With Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis
- Efficacy of Pirfenidone Plus MODD in Diabetic Foot Ulcers
- Clinical Progression of Mild to Moderate Idiopathic Pulmonary Fibrosis (IPF) Under a Therapy With Esbriet® (Pirfenidone)
- A Study to Compare the Amount of Nintedanib and Pirfenidone in the Blood When Nintedanib and Pirfenidone Are Given Separately or in Combination
- Safety and Tolerability Study of Pirfenidone in Combination With Nintedanib in Participants With Idiopathic Pulmonary Fibrosis (IPF)
- Safety and Efficacy of Allogeneic Mesenchymal Stem Cells in Patients With Rapidly Progressive Interstitial Lung Disease
- Safety, Tolerability and PK of Nintedanib in Combination With Pirfenidone in IPF
- Pirfenidone Effect on the Recovery of Renal Function in Septic Acute Kidney Injury
- A Bioequivalence Study Comparing Pirfenidone Tablet and Capsule Dosage Forms in Healthy Adult Participants
- Pirfenidone in the Chronic Hypersensitivity Pneumonitis Treatment
- Treatment of Refractory Chronic Cough With PA101
- Utility of Prolonged-release Pirfenidone in the Progression of Chronic Kidney Disease
- Safety and Efficacy Study of Pirfenidone to Treat Grade 2 or Above Radiation-induced Lung Injury
- European Trial of Pirfenidone in BOS, A European Multi-center Study
- Effect of Topic Pirfenidone in Diabetic Ulcers
- Pirfenidone, an Antifibrotic and Antiinflammatory Drug
- Expanded Access Program (EAP): Allow Patients in the US With Idiopathic Pulmonary Fibrosis Access to Pirfenidone
- Clinical Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis
- Effect of Fostair® on Biomarkers of Platelet Adhesion in Idiopathic Pulmonary Fibrosis
- Safety and Tolerability of Pirfenidone in Participants With Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD) (LOTUSS)
- Evaluate the Safety and Efficacy of FG-3019 (Pamrevlumab) in Participants With Idiopathic Pulmonary Fibrosis (IPF)
- A Study of Lebrikizumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
- Safety and Efficacy Study of Pirfenidone to Treat Idiopathic Pulmonary Fibrosis(IPF)
- Safety and PK Study of BIBF 1120 in Japanese Patients With IPF: Follow up Study From 1199.31(NCT01136174)
- Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- Safety and PK Study of BIBF 1120 in Japanese Patients With IPF
- Clinical Trial of Pirfenidone in Adult Patients With Neurofibromatosis 1
- Open-Label Study of the Long Term Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- Pilot Study of a Multi-Drug Regimen for Severe Pulmonary Fibrosis in Hermansky-Pudlak Syndrome
- Development of a Non-Invasive Treatment for Uterine Leiomyoma (Fibroids)
- Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis
- Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis
- Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
- Pirfenidone in Children and Young Adults With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas
- Pirfenidone: A New Drug to Treat Kidney Disease in Patients With Diabetes
- Pirfenidone in Treating Young Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas
- Pirfenidone in Treating Patients With Fibrosis Caused by Radiation Therapy for Cancer
- Pirfenidone to Treat Hypertrophic Cardiomyopathy
- Permeability Factor in Focal Segmental Glomerulosclerosis
- Pirfenidone to Treat Kidney Disease (Focal Segmental Glomerulosclerosis)
- Oral Pirfenidone for the Pulmonary Fibrosis of Hermansky-Pudlak Syndrome
Clinical trials list
click for details